Lion TCR is a clinical-stage biotechnology company.
Lion TCR has raised $41.6M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Lion TCR's investors include Guangzhou Industrial Investment Group, Guangzhou Guoju Venture Capital, Westlake Venture Partners, CSPC NARD Capital, Yashang Capital.
Lion TCR is headquartered in Singapore, Singapore.
Lion TCR is a clinical-stage biotechnology company.
Lion TCR is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lion TCR — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/lion-tcr. Accessed August 14, 2026.
VCBacked. (2023). Lion TCR — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lion-tcr
{{cite web |title=Lion TCR — Funding & Investors |url=https://www.vcbacked.co/company/lion-tcr |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated